Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Nasus Pharma Ltd., a foreign private issuer, covers the month of March 2026. The report details the results of a Special General Meeting of Shareholders held on March 5, 2026, in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and does not contain financial performance data.
Material Changes
Shareholders approved all agenda items presented at the Special General Meeting. The primary material change is the amendment and restatement of the Company's Articles of Association to increase its authorized share capital.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the shareholder vote and the execution of the amended Articles of Association.
Key Facts for Investor Verification
- Shareholders approved the increase of authorized share capital on March 5, 2026.
- The Amended and Restated Articles of Association are filed as Exhibit 99.1.
- The meeting achieved a quorum and passed all items by the required majority.
- No financial results or operational updates are included in this specific filing.